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Several genes conferring susceptibility to breast and ovarian cancer, notably BRCA1 and BRCA2, have been identified. The majority
of the familial aggregation of breast cancer is, however, not explained by these genes. We have previously derived, using segregation
analysis, a susceptibility model (BOADICEA, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) in
which susceptibility to these genes is explained by mutations in BRCA1 and BRCA2 together with a polygenic component reflecting
the joint multiplicative effect of multiple genes of small effect on breast cancer risk. Here, we consider the predictions made by this
model. The overall familial risks of breast cancer predicted by this model are close to those observed in epidemiological studies. The
predicted prevalences of BRCA1 and BRCA2 mutations among unselected cases of breast and ovarian cancer are also consistent
with observations from population-based studies. These predictions are closer to the observed values than those obtained using the
Claus model and BRCAPRO. The predicted mutation probabilities and cancer risks in individuals with a family history (FH) can differ
markedly from those predicted by other models. We conclude that this model provides a rational basis for risk assessment in
individuals with a FH of breast or ovarian cancer.
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Genetic testing for the breast and ovarian cancer susceptibility
genes BRCA1 and BRCA2 can help in the clinical management of
individuals with family history (FH) of the disease, by identifying
individuals at highest risk. Those individuals can then be offered
screening from an earlier age, prophylactic mastectomy or
oophorectomy or potentially chemoprevention, for example, with
tamoxifen (Hartmann et al, 2001; Meijers-Heijboer et al, 2001;
King et al, 2001). However, genetic testing is expensive and may be
associated with adverse psychosocial effects (Burke et al, 1997;
Davis, 1997). Therefore, to provide an effective genetic counselling
service, it is important that genetic testing is targeted towards
those individuals most likely to prove positive.
Mathematical models, which predict carrier probabilities and
cancer risks, can provide a rational basis for counselling. A
number of models, which address the problem of predicting the
BRCA1 and BRCA2 carrier risks and/or the breast and ovarian
risks have been reported in the literature (Gail et al, 1989; Claus
et al, 1991, 1994; Shattuck-Eidens et al, 1995; Couch et al, 1997;
Parmigiani et al, 1998; Apicella et al, 2003). Several of these are
logistic regression models that utilise descriptive measures of FH.
Such models are straightforward to implement and have the
advantage that other nongenetic risk factors can readily be
incorporated (Gail et al, 1989; Shattuck-Eidens et al, 1995; Couch
et al, 1997; Apicella et al, 2003). The disadvantage with this
approach is that it cannot deal adequately with complex family
histories. An alternative approach is to base predictions on a
genetic model for the disease. The first genetic model to be widely
used was developed by Claus et al (1991, 1994). This allows for a
single highly penetrant gene, which is dominantly inherited. A
more recent model, developed by Parmigiani et al (1998) and
implemented in the computer software BRCAPRO (Berry et al,
2002) allows for the simultaneous effect of BRCA1 and BRCA2.
However, recent research has indicated that genetic susceptibility
to breast cancer is more complex than these models suggest.
Epidemiological studies have demonstrated that BRCA1 and
BRCA2 mutations account for less than 20% of the familial
aggregation of breast cancer (Easton 1999; Peto et al, 1999). An
adequate genetic model for breast cancer must clearly reflect the
existence of other susceptibility genes.
In a previous article, we described the development of a genetic
model for familial breast cancer, which takes into account the
simultaneous effects of BRCA1, BRCA2 and other genes (Antoniou
et al, 2002). In this article, we investigate the predictions of this
model. We compute cancer risks and mutation carrier probabil-
ities for a variety of different scenarios. The predicted results are
compared with those from epidemiological studies and contrasted
with the results of other models.
MATERIALS AND METHODS
The model
The analyses in this article are based on the best fitting model
found by Antoniou et al (2002). This model was developed using
complex segregation analysis of breast and ovarian cancer
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soccurrence in a combined data set of a population-based series of
1484 breast cancer cases and 156 multiple-case families. Briefly, the
model allows for the simultaneous effects of BRCA1, BRCA2, with
disease allele frequencies 0.051% and 0.065%, respectively, and the
effect of low-penetrance genes with multiplicative effects on the
breast cancer risk (Antoniou et al, 2002). It also allows for the
effect of genetic modifiers, which cluster in families and alter the
breast cancer risks in BRCA1 and BRCA2 carriers. Under this
model, the incidence of breast cancer at age t is given by
lkðtÞ¼lk;0ðtÞexpðXÞ
where k¼0,1,2 for noncarriers, BRCA1 and BRCA2 carriers,
respectively. X is a polygenic component, assumed to be normally
distributed with mean 0 and variance s
2 and is independent of age.
s
2 is estimated to be 1.67; it is assumed to be the same in BRCA1
and BRCA2 carriers and noncarriers (Antoniou et al (2002) found
no significant difference in s
2 between carriers and noncarriers).
Ovarian cancer rates follow a similar model but with no polygenic
component. Other cancers are ignored in this model. The baseline
incidence rates lk,0(t) are given in Table 1. These incidence rates
are chosen so that the overall age-specific incidence for both
diseases, averaged over all genotypes, is constrained to agree with
population incidence rates – in this implementation these are the
rates for England and Wales over the period 1983–1987. Ovarian
and breast cancer risks are assumed to be independent given the
genotype. In the current implementation, only females are
susceptible to breast cancer. The cumulative breast cancer risk,
averaged over all possible modifiers, is 35% by age 70 years for
BRCA1 carriers and 50% for BRCA2 carriers; the corresponding
ovarian cancer risks are 26% for BRCA1 carriers and 9.1% for
BRCA2 carriers. Nonmutation carriers have a cumulative risk of
5% of developing breast cancer and 1% probability of developing
ovarian cancer by age 70 years. The model is implemented in the
pedigree analysis computer program MENDEL v3.3 (Lange et al,
1988). This program allows genotype probabilities and cancer risks
to be derived for pedigrees of arbitrary structure. We have named
this model BOADICEA (Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm). The routines to
implement this model are available from the authors on request.
Information on testing for BRCA1 and BRCA2 mutations can
also be taken into account. In this implementation, mutations are
assumed to be clearly pathogenic (i.e. mutation testing is 100%
specific) but mutation detection sensitivity can be varied. In the
examples presented here, the sensitivity is assumed to be 100%
(that is, the probabilities refer to the probabilities of a mutation
being present, not necessarily the probabilities of a mutation being
detected). The possibility of both BRCA1 and BRCA2 mutations in
the same individual is ignored.
Carrier probabilities
The probability that an individual carries a BRCA1 or a BRCA2
mutation based on the FH information can be computed using
Bayes theorem. For example,
PðBRCA1carrierjFHÞ¼
PðBRCA1carrier;FHÞ
P
i PðBRCAicarrier;FHÞ
¼
L1
L0 þ L1 þ L2
where Li is the likelihood of observing the family with the index
individual carrying mutation i (¼0, 1, 2 for mutation negative,
BRCA1 and BRCA2, respectively). These likelihoods can be
generated in MENDEL.
Cancer risks
We computed the probability that a woman of a given age x years
developed breast or ovarian cancer by age xþn, given the known
FH. For example, if we denote the event of breast cancer by BC and
the event of being unaffected by U, then
PðBCbyagexþnjU atagex;FHÞ¼
P½BCbetweenagesðx;xþnÞ;FH 
P½U atagex;FH 
The denominator corresponds to the likelihood of observing the
pedigree with the individual being unaffected at age x. The
numerator is equivalent to the likelihood of observing the family,
but replacing the penetrance for the index case by
X n 1
k¼0
lðx þ kÞSbðx þ kÞSoðx þ kÞ
where l(x) is the breast cancer incidence at age x, and S
b(t) and
S
o(t) are the probabilities of remaining free of breast and ovarian
cancer respectively by age t. Hence, the risks can be computed as
the ratio of two likelihoods.
Breast cancer familial relative risks (FRRs)
We define the FRR of breast cancer to a relative of a breast cancer
patient to be the ratio of the risk to the relative to the population
risk (Risch, 1990). The FRR predicted by the model can also be
computed from two likelihoods using MENDEL. For example, in
the case of FRR to daughters
FRR ¼
PðDaughteraffectedatagetjMotheraffectedatagetÞ
PðDaughteraffectedatagetÞ
¼
PðDaughteraffectedataget;MotheraffectedatagetÞ
PðDaughteraffectedatagetÞPðmotheraffectedatagetÞ
Note that all probabilities refer to the density of the risk
distribution (i.e. probability of being affected at age t) rather than
the incidence rates. These probabilities are therefore comparable
to those derived from case–control studies. The FRR calculated
above varies by age. To calculate an overall FRR, the age-specific
FRRs were averaged over ages 20–70 years, weighted by the age
distribution of breast cancer cases in the population.
Table 1 Baseline BRCA1, BRCA2 and noncarriers’ breast cancer incidence rates and corresponding ovarian cancer incidence rates used in the
proportional-hazards model (Antoniou et al, 2002)
Baseline breast cancer incidence rate (%) Ovarian cancer incidence rate (%)
Age (years) Noncarriers BRCA1 BRCA2 Noncarriers BRCA1 BRCA2
30 0.009 0.538 0.375 0.004 0.021 0.022
40 0.040 1.021 0.799 0.012 1.173 0.044
50 0.068 0.677 1.484 0.031 0.813 0.462
60 0.092 0.450 2.612 0.044 0.976 0.416
70 0.114 0.481 3.591 0.048 0.100 0.100
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The segregation analysis used to derive the BOADICEA model
considered only the occurrence of the first cancer in an individual
(breast or ovary), and does not therefore make any direct
predictions about the risks of a contralateral breast cancer.
Predictions can be made, however, if one assumes that the
increased risks of contralateral breast cancer (relative to popula-
tion rates) are entirely due to susceptibility as defined by the
model, that is, there is no additional individual variation in risk.
Under this model, the contralateral breast cancer incidence rate
after the first breast cancer, given the genotype, is half the
incidence rate assumed in the standard model, to allow for only
one breast being at risk. Ovarian cancer incidence rates after a
breast cancer are assumed to be the same as if the breast cancer
had not occurred (conditional on genotype) consistent with the
assumption of independence between breast and ovarian cancer
risks.
RESULTS
Mutation carrier probabilities
Table 2 shows the predicted carrier probabilities for a female,
who has developed breast or ovarian cancer unselected for FH,
together with the corresponding probabilities given by BRCAPRO
(CancerGene v3.1, http://www3.utsouthwestern.edu/cancergene).
Note that because the relative risk parameters for BRCA1
and BRCA2 were estimated by decade, and the population
incidence rates change at every 5-year interval, the mutation
prevalence predicted by the BOADICEA model is essentially
constant over each 5-year interval. The model predicts that
among women who develop breast cancer at age 30 years,
approximately 10% carry a BRCA1 or a BRCA2 mutation. The
carrier probability drops with age to approximately 1% for women
diagnosed at age 70 years. The carrier probabilities given by
BRCAPRO are 6.3 and 0.1% for women diagnosed at ages 30 and
70 years, respectively. The same table shows the predicted
contributions of BRCA1 and BRCA2 to cases diagnosed with
ovarian cancer. The contribution of BRCA1 is low below age 40
years, highest at age 40 years and declines thereafter. The
contribution of BRCA2 mutations to ovarian cancer is predicted
to be highest at age 50 years (1.6%). This later peak for BRCA2 is
consistent with observations from previous studies (Risch et al,
2001). The BRCAPRO predicted carrier probabilities demonstrate
similar patterns.
The carrier probabilities for an individual who has developed
breast cancer and has a mother diagnosed with breast cancer at
different ages are shown in Table 3. Both BRCA1 and BRCA2
carrier probabilities decrease with increasing age at diagnosis of
the index individual and her mother. The decrease is more marked
for BRCA1 than for BRCA2, so that the prevalence of BRCA1
mutations is higher than BRCA2 at younger ages but lower at older
ages. The BRCA1 probabilities are consistently lower than the
BRCAPRO predictions, particularly at young ages, while the
BRCA2 probabilities are markedly higher.
Table 4 shows the predicted BRCA1/2 mutation carrier
probabilities for breast cancer cases with an affected mother and
sister at different ages. As expected, the carrier probabilities are
higher when an individual has two relatives diagnosed with the
disease as compared with one affected relative. The BRCA2 carrier
probabilities are higher than the BRCA1 probabilities, except
where at least two of the cases are diagnosed below age 40 years.
The difference is particularly marked when all cases are diagnosed
at ages 50 years and over, when the BRCA1 carrier probability is
low.
Table 2 Predicted BRCA1 and BRCA2 carrier probabilities for breast
and ovarian cancer cases unselected for family history
Breast cancer Ovarian cancer
Age at
onset
(years) BRCA1 BRCA2 BRCA1 BRCA2
30 0.051 (0.055) 0.050 (0.008) 0.006 (0.001) 0.008 (0.000)
40 0.016 (0.029) 0.020 (0.005) 0.082 (0.026) 0.004 (0.003)
50 0.004 (0.012) 0.015 (0.004) 0.018 (0.039) 0.016 (0.006)
60 0.002 (0.003) 0.012 (0.003) 0.013 (0.013) 0.008 (0.005)
70 0.001 (0.000) 0.008 (0.001) 0.001 (0.004) 0.001 (0.004)
Corresponding probabilities using BRCAPRO within parentheses.
Table 3 Predicted BRCA1/2 carrier probabilities for a breast cancer case whose mother developed breast cancer
Age at onset of breast cancer for mother (years)
Index age at onset (years) 30 40 50 60 70
30
BRCA1 0.400 (0.566) 0.223 (0.415) 0.075 (0.244) 0.045 (0.103) 0.042 (0.049)
BRCA2 0.318 (0.036) 0.221 (0.034) 0.196 (0.037) 0.153 (0.030) 0.102 (0.020)
40
BRCA1 0.212 (0.407) 0.087 (0.270) 0.025 (0.144) 0.014 (0.056) 0.013 (0.025)
BRCA2 0.211 (0.033) 0.107 (0.028) 0.082 (0.027) 0.062 (0.021) 0.041 (0.013)
50
BRCA1 0.056 (0.228) 0.020 (0.137) 0.006 (0.067) 0.003 (0.024) 0.003 (0.011)
BRCA2 0.180 (0.035) 0.080 (0.027) 0.061 (0.024) 0.047 (0.018) 0.032 (0.011)
60
BRCA1 0.023 (0.079) 0.008 (0.043) 0.002 (0.020) 0.001 (0.007) 0.001 (0.003)
BRCA2 0.134 (0.028) 0.058 (0.020) 0.045 (0.017) 0.036 (0.012) 0.025 (0.007)
70
BRCA1 0.019 (0.022) 0.006 (0.011) 0.002 (0.005) 0.001 (0.001) 0.001 (0.000)
BRCA2 0.080 (0.016) 0.034 (0.011) 0.028 (0.009) 0.024 (0.006) 0.017 (0.004)
Corresponding probabilities using BRCAPRO within parentheses.
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To investigate the consistency of our model with results from
epidemiological studies, we computed the FRRs predicted by our
model. Table 5 shows the FRR of breast cancer at different ages,
associated with a mother diagnosed with breast cancer. Also shown
for comparison are the FRRs published in the largest combined
analysis of familial risks (Collaborative Group in Hormonal
Factors in Breast Cancer, 2001), and the corresponding predictions
using the Claus et al, (1991) model and BRCAPRO. The Claus
model was implemented in MENDEL using the parameter
estimates reported in Claus et al (1991). The FRR predicted by
our model decreases with age from 5.66 at age 30 years to 1.65 at
age 70 years. The predicted relative risk at age 25 years (3.36) is
lower than that at age 30 years, but the incidence rates in carriers
are particularly imprecise at this age (Antoniou et al, 2002). The
predicted relative risk in the 40–49 years age group is very similar
to the published estimates from the Collaborative Group analysis.
At older ages the predictions are slightly higher than the observed
values. The Claus model predicts a higher relative risk than
BOADICEA at ages 45 years and below, but a lower relative risk at
ages 50 years and above. There is a marked difference between the
Claus model predictions and the Collaborative group estimates at
ages 60 years and above. The relative risks predicted by BRCAPRO
are much lower than the Collaborative group estimates at all ages.
They are also lower than the BOADICEA and Claus et al
predictions. The intraclass correlation coefficient between the
BOADICEA predictions and the Collaborative group estimates is
estimated to be 0.99. The corresponding coefficients for the Claus
et al model and BRCAPRO are 0.99 and 0.35.
Table 4 Predicted BRCA1/2 carrier probabilities for a breast cancer case whose mother and sister have developed breast cancer
Age of BC onset of index: 30years Age of BC onset of index: 40 years Age of BC onset of index: 50 years
Age of BC onset of sister (years) Age of BC onset of sister (years) Age of BC onset of sister (years)
Age of BC onset of mother (years) 30 40 50 60 70 30 40 50 60 70 30 40 50 60 70
30
BRCA1 0.577 0.497 0.275 0.239 0.288 0.467 0.367 0.170 0.127 0.140 0.186 0.126 0.047 0.031 0.033
BRCA2 0.387 0.427 0.575 0.544 0.429 0.403 0.396 0.453 0.393 0.287 0.510 0.428 0.405 0.336 0.243
40
BRCA1 0.498 0.389 0.179 0.135 0.149 0.367 0.231 0.084 0.055 0.054 0.126 0.064 0.020 0.012 0.012
BRCA2 0.427 0.419 0.476 0.411 0.300 0.397 0.308 0.281 0.218 0.147 0.426 0.267 0.215 0.165 0.111
50
BRCA1 0.274 0.179 0.065 0.044 0.047 0.169 0.084 0.026 0.016 0.015 0.046 0.020 0.006 0.003 0.003
BRCA2 0.577 0.478 0.444 0.364 0.262 0.454 0.281 0.224 0.171 0.115 0.402 0.214 0.165 0.127 0.086
60
BRCA1 0.237 0.134 0.044 0.028 0.029 0.127 0.054 0.016 0.009 0.009 0.031 0.012 0.003 0.002 0.002
BRCA2 0.549 0.414 0.365 0.295 0.210 0.394 0.219 0.171 0.132 0.089 0.334 0.165 0.127 0.099 0.068
70
BRCA1 0.286 0.148 0.046 0.029 0.028 0.140 0.054 0.015 0.009 0.008 0.033 0.012 0.003 0.002 0.002
BRCA2 0.433 0.302 0.262 0.209 0.146 0.288 0.147 0.115 0.089 0.060 0.241 0.111 0.086 0.068 0.047
Age of BC onset of index: 60 years Age of BC onset of index: 70years
Age of BC onset of sister (years) Age of BC onset of sister (years)
Age of BC onset of mother 30 40 60 60 70 30 40 50 60 70
30
BRCA1 0.100 0.061 0.021 0.013 0.013 0.101 0.057 0.019 0.011 0.011
BRCA2 0.439 0.340 0.312 0.260 0.186 0.279 0.207 0.194 0.164 0.117
40
BRCA1 0.061 0.028 0.008 0.005 0.005 0.057 0.024 0.007 0.004 0.004
BRCA2 0.339 0.193 0.155 0.122 0.083 0.206 0.111 0.091 0.074 0.051
50
BRCA1 0.021 0.008 0.002 0.001 0.001 0.019 0.007 0.002 0.001 0.001
BRCA2 0.309 0.154 0.120 0.096 0.066 0.192 0.091 0.073 0.060 0.042
60
BRCA1 0.013 0.005 0.001 0.001 0.001 0.011 0.004 0.001 0.001 0.001
BRCA2 0.256 0.120 0.095 0.077 0.054 0.161 0.073 0.059 0.049 0.035
70
BRCA1 0.013 0.005 0.001 0.001 0.001 0.011 0.004 0.001 0.001 0.001
BRCA2 0.183 0.082 0.065 0.054 0.038 0.115 0.050 0.041 0.035 0.025
BC¼breast cancer.
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sisters of breast cancer patients
Peto and Mack (2000) have noted that the risk of risk of
contralateral breast cancer is approximately constant at 0.7% per
annum, regardless of the age at diagnosis of first cancer or the time
since the first cancer. They further note that breast cancer in
monozygotic twins of breast cancer patients is approximately
constant, at 1.4% per annum, following the age at diagnosis of the
co-twin, and that the risk of breast cancer to sisters of breast
cancer cases is approximately constant at 0.35% per annum. We
have evaluated the consistency of BOADICEA model with these
observations.
Table 6 shows the predicted incidence in a sister of a breast
cancer patient, at ages older than the age at onset of the patient’s
breast cancer. Under the BOADICEA model, most of the incidence
rates are in the range 0.3–0.45%, in line with the suggestion of
Peto and Mack. However, the incidence rates increase slightly with
age. The most marked discrepancy is below age 40 years, for cases
diagnosed at age 30 years, where the predicted rate is 0.16%. For
comparison the table includes the reported incidence rates in
mothers and sisters in the two studies reported by Peto and Mack
(2000). Of the 10 cells where there are estimates from both studies,
the predicted incidence lies between the two estimates in five,
lower than both estimates in four and higher than both in one. The
intraclass correlation coefficient between the BOADICEA predic-
tions and the Peto and Mack estimates is 0.36. Table 6 also shows
the predicted annual incidence under the Claus et al model and
BRCAPRO. The intraclass correlation coefficients for these
predictions with the Peto and Mack estimates were 0.34 and
0.07, respectively, indicating that the agreement between the
BRCAPRO predictions and the observed values is poorer than the
corresponding BOADICEA or Claus et al predictions.
The predicted incidence in the monozygotic twin following the
diagnosis of breast cancer in their co-twin is shown in Table 7. The
predicted incidence under the BOADICEA model is approximately
twice that of the corresponding incidence in a sister. Moreover, as
in the case of sisters, the incidence is not constant over the years
after the first twin’s diagnosis, but increases slightly over time.
Similar patterns are observed for the predicted incidence under the
Claus et al model. However, under BRCAPRO the predicted
incidence in a monozygotic twin of a breast cancer patient is very
similar to the incidence in sisters (Table 6).
Table 8 shows the annual incidence of contralateral breast
cancer predicted by the BOADICEA model, as modified to allow
for second cancers. Overall the contralateral incidence rate is about
half the incidence in a monozygotic twin of a breast cancer case in
the years after the first twin’s diagnosis. Again, the incidence
increases slightly with the years since diagnosis of the first cancer,
although the increase is only marked for cases diagnosed below age
45 years. The same table shows the predictions under the Claus
et al model, which was modified in a similar manner to allow for
contralateral breast cancer. Similar patterns were observed to the
BOADICEA predictions. The predicted incidence of contralateral
breast cancer under the Claus model is in general somewhat lower
than the BOADICEA incidence in the 10 years just after the first
diagnosis, but higher thereafter.
Genetic modification of risk in BRCA1 and BRCA2 carriers
Under the BOADICEA model, the polygenic component is
assumed to act on both carriers and noncarriers of BRCA1 and
Table 5 Age-specific breast cancer familial relative risks associated with
family history in a first-degree relative (mother)
Predicted relative risk
Age (years) BOADICEA Claus et al BRCAPRO Observed
a
25 3.36 10.33 2.87
30 5.66 6.13 2.24 5.7
35 2.47 5.63 1.76
40 2.18 2.32 1.33 2.0
45 1.92 2.00 1.16
50 1.87 1.51 1.08 1.6
55 1.80 1.37 1.03
60 1.76 1.10 1.01
65 1.70 1.07 1.00 1.4
70 1.65 1.05 1.00
For the predicted relative risks, we assume the same age diagnosis for the mother and
the index case.
aCollaborative Group on Hormonal Factors in Breast Cancer (2001).
Table 6 Predicted annual incidence (%), in a sister of a breast cancer patient, at ages older than the index patient’s age at diagnosis
Age of sister (years)
Index age at diagnosis (years) 30–39 40–49 50–59 60–69 70–79
30 0.14 0.30 0.35 0.41 0.44
0.10(B) 0.24(B) 0.30(B) 0.34(B) 0.33(B)
0.20(C) 0.43(C) 0.39(C) 0.42(C) 0.80(C)
(0.33,0.14) (0.78, 0.25) (0.49, 0.52) (0.78) (—)
35 0.25 0.32 0.39 0.42
0.22(B) 0.29(B) 0.33(B) 0.33(B)
0.42(C) 0.38(C) 0.41(C) 0.77(C)
(0.40,0.34) (0.43,0.39) (0.24, 0.44) (0.69, 0.20)
45 0.30 0.38 0.41
0.27(B) 0.32(B) 0.33(B)
0.25(C) 0.31(C) 0.54(C)
(0.28,0.40) (0.34, 0.23) (0.42, 0.45)
55 0.37 0.41
0.32(B) 0.32(B)
0.28(C) 0.46(C)
(0.36) (0.48)
B¼BRCAPRO predictions; C¼Claus et al predictions. Within parentheses are the reported annual incidence rates in the two studies of the analysis of Peto and Mack (2000).
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variance of the polygenic component did not vary significantly
between carriers and noncarriers. A consequence of this model is
that the absolute risk of breast cancer in a carrier will depend on
FH. To illustrate this, we calculated the risks to a healthy 40-year-
old female BRCA2 mutation carrier according to her FH of breast
cancer, as illustrated in Figure 1. For a BRCA2 carrier without any
information on FH, the predicted absolute risk of breast cancer by
age 60 years is 30%. If we assume that the woman has two sisters
unaffected at ages 45 and 50 years, respectively, and that her
mother died at age 40 years without developing breast cancer, then
her predicted risk reduces to 27%. If we assume that her mother
had developed breast cancer at age 40 years, then the predicted risk
increases to 38%. If in addition to the mother, one sister is
assumed to have developed breast cancer at age 45 years, the
predicted breast cancer risk by age 60 years rises to 48%. Finally, if
both of her sisters and her mother are assumed to have developed
breast cancer, her risk rises to 55%.
Predictions in high-risk families
To examine the predictions of our model in women with a strong
FH, we have considered two families where the index case was
participating in the MARIBS study of MRI screening for women at
a high risk of breast cancer (Brown et al, 2000; Leach et al, 2002).
These families are thus examples of ‘high-risk’ families seen at
cancer genetics clinics. For these families, we have compared our
predictions with those given by BRCAPRO (CancerGene v3.1,
http://www3.utsouthwestern.edu/cancergene) and the Claus model
(Claus et al, 1991). The Claus model takes into account breast
cancer but not ovarian cancer occurrence in the family. In the first
example, the consultant is 40 years old and unaffected with cancer.
Her mother and one maternal aunt developed ovarian cancer and
another two maternal aunts developed breast cancer at ages 35 and
49 years (Figure 2). The BOADICEA model predicts that she carries
a BRCA1 mutation with a probability of 40.9% and a BRCA2
mutation with a probability of 1.3%. In this example, the carrier
probabilities given by BRCAPRO are similar: 39.3% and 1.6% for
BRCA1 and BRCA2, respectively. The predicted risk of breast
cancer by age 70 years under the BOADICEA model is 13%
(Figure 3). This is similar to that predicted by the Claus model
(11%) but much lower than that predicted by BRCAPRO (29%).
BOADICEA also predicts a lower risk of ovarian cancer (9% by age
70 years ) than BRCAPRO (12%).
The second family is shown in Figure 4. The female seeking
genetic counselling is 45 years old and has several relatives
diagnosed with breast cancer, including her mother, sister,
maternal grandmother and two maternal great aunts. Our model
predicts that she carries a BRCA1 mutation with probability of
2.3% and a BRCA2 mutation with probability 30.1%. These
compare with BRCAPRO probabilities of 17% for BRCA1 and 2.4%
Table 7 Predicted annual breast cancer incidence (%) in a monozygotic
twin in the years after the diagnosis in the first twin
Years since first twin’s diagnosis (years)
First twin age (years) o5 5–9 10–14 15+
35 0.25 0.43 0.55 0.68
0.17(B) 0.26(B) 0.30(B) 0.34(B)
0.34(C) 0.77(C) 0.70(C) 0.85(C)
40 0.40 0.52 0.55 0.70
0.22(B) 0.26(B) 0.29(B) 0.33(B)
0.46(C) 0.42(C) 0.41(C) 0.56(C)
45 0.49 0.53 0.58 0.70
0.24(B) 0.27(B) 0.30(B) 0.33(B)
0.38(C) 0.37(C) 0.34(C) 0.57(C)
50 0.52 0.57 0.65 0.71
0.26(B) 0.29(B) 0.32(B) 0.33(B)
0.31(C) 0.29(C) 0.36(C) 0.52(C)
55 0.55 0.63 0.68 0.71
0.28(B) 0.31(B) 0.33(B) 0.33(B)
0.26(C) 0.34(C) 0.32(C) 0.57(C)
B¼BRCAPRO predictions; C¼Claus et al predictions.
Table 8 Predicted annual incidence (%) of contralateral breast cancer
Years since first breast cancer (years)
Age at first cancer (years) o5 5–9 10+
35 0.15 (0.18) 0.25 (0.42) 0.37 (0.64)
40 0.23 (0.26) 0.30 (0.25) 0.37 (0.42)
45 0.29 (0.24) 0.30 (0.24) 0.37 (0.43)
50 0.31 (0.20) 0.32 (0.19) 0.39 (0.40)
55 0.34 (0.18) 0.36 (0.22) 0.39 (0.43)
Within parentheses are the Claus et al predictions.
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Figure 1 Predicted risks of breast cancer by age 60 years, to a 40-year-old female BRCA2 mutation carrier according to her FH of breast cancer.
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individual are summarised in Figure 5. BOADICEA gives the
highest breast cancer risk by age 70 years (28%) by age 70 and
BRCAPRO the lowest (16%). The age-specific breast cancer risks
given by the Claus et al model (25% by age 70 years) are similar to
those predicted under our model.
Although for the age-specific cancer risks given by the Claus et al
model were similar to those given by BOADICEA in both the above
examples, this is not true generally. For example, consider
individual 301 in Figure 6, who is unaffected at age 34 years.
Under BOADICEA, her estimated risk by age 70 years is
approximately 12%, whereas the predicted risk under the Claus
model is 24%.
DISCUSSION
The BOADICEA model is a general model of breast cancer
susceptibility that can provide estimates of cancer risks and carrier
probabilities to women with a FH of breast/ovarian cancer.
However, before using such a model in clinical practice, it is
important to evaluate the accuracy of its predictions in indepen-
dent data sets that were not used to derive the model. A number of
such validation studies have recently been reported for other
models, including BRCAPRO and Claus (Amir et al, 2003, Marroni
et al, 2004, Evans et al, 2004), and have identified some model
deficiencies while suggesting ways of refining the algorithms. In
this paper, we have examined the frequencies of the BRCA1 and
BRCA2 mutations in unselected series of breast cancer patients,
and the FRRs of breast cancer, predicted by the BOADICEA model,
since these can be compared with empirical observations.
Several studies have investigated the prevalence of BRCA1 and
BRCA2 mutation in series of breast cancer cases unselected for FH
in nonfounder populations (i.e. excluding populations such as the
Ashkenazi Jewish or Icelandic populations where there are
prevalent founder mutations) (Langston et al, 1996; Peto et al,
1999; Hopper et al, 1999; Malone et al, 2000). The pattern of
predicted age-specific contributions of BRCA1 and BRCA2
mutations to breast cancer (Table 2) is generally in line with the
78
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Figure 2 Family 1 with information on age at last follow-up and age at
diagnosis. Index indicated by arrow. BC¼breast cancer; OC¼ovarian
cancer.
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Figure 3 Predicted cancer risks for the index female of family 1 under
the following models: BOADICEA, BRCAPRO (CancerGene v3.1, http://
www3.utsouthwestern.edu/cancergene) and Claus et al (1991).
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Figure 4 Family 2 with information on age at last follow-up and age at diagnosis. Index indicated by arrow. BC¼breast cancer.
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sresults of the population studies, where the contribution is highest
at young ages at onset and thereafter it decreases. Direct
comparison with empirical observations is complicated by the
fact that these studies have used different screening techniques,
with different sensitivities. However, in the only other UK study to
screen the coding sequences of both genes, Peto et al (1999) used
the same technique (CSGE) as the studies on which BOADICEA
was based. They estimated that 3.5% of women diagnosed under
age 36 years carried a BRCA1 mutation and 2.4% carried a BRCA2
mutation. Assuming similar mutation detection sensitivity
(B70%) for CSGE used in the development of BOADICEA, the
corresponding contributions predicted by our model are 3.4% for
BRCA1 and 1.3% for BRCA2, very similar for BRCA1 but
somewhat lower for BRCA2 than the observed proportions. In
the Peto et al study (Peto et al, 1999), BRCA1 and BRCA2 were
estimated to account for 1.9% and 2.2% of unselected breast
cancers diagnosed between ages 36 and 45 years. These are
somewhat higher than the contributions predicted by BOADICEA
(1.3% for BRCA1, 1.5% for BRCA2) but consistent given the small
number of mutations. By comparison, the predictions under the
BRCAPRO model are 3.7% and 0.6% for BRCA1 and BRCA2,
respectively, for cases diagnosed under age 36 years and 1.8% and
0.4% for breast cancers diagnosed between ages 36 and 45 years.
Thus, the BRCA2 predictions from BOADICEA are much closer to
the observed values. The prevalence of mutations in breast and
ovarian cancer cases in the Ashkenazi and Icelandic populations is
higher; to be applicable to these populations, the model will need
to be adapted to use higher allele frequencies. Alterations to the
allele frequencies may also be required for other populations with
more limited numbers of mutations, for example, the Polish,
French Canadian and Dutch populations.
We also compared the age-specific breast cancer risks to women
with a first-degree FH of breast cancer with those reported in
epidemiological studies. The age-specific FRRs predicted by our
model are similar to the estimates of the meta-analysis reported by
the Collaborative Group in Hormonal Factors in Breast Cancer
(2001), with a gradual decline in relative risk with age of the
consultand and age at diagnosis of the relative. The main
difference is at older ages, where the predicted relative risks are
somewhat greater than the observed values. By comparison, the
Claus et al (1991) model fits poorly at older ages, particularly
beyond age 60 years, while the predicted relative risks from
BRCAPRO are substantially lower than the observed values at all
ages. The latter result was expected as BRCAPRO takes into
account only BRCA1 and BRCA2, which explain about 20% of the
excess FRR of breast cancer (Parmigiani et al, 1998; Easton, 1999;
Peto et al, 1999).
Peto and Mack (2000) examined the risks of contralateral breast
cancer and noted that the incidence rates were approximately 0.7%
per annum, independent of age. They also noted that the risks of
breast cancer in monozygotic twins and sisters of cases were also
approximately constant over time after the age at diagnosis of their
relative, at approximately 1.4 and 0.35%, respectively. They
postulated that such effects might be due to a model in which
the risk of breast cancer reaches a constant high level at a
genetically determined age. This concept is different from that
underlying the polygenic model in BOADICEA, in which multiple
genes ‘interact’ multiplicatively to increase risk at all ages. It was
therefore particularly interesting to examine the predictions of
these risks made by the BOADICEA model. The predicted annual
incidence of breast cancer in sisters of breast cancer patients at
ages older than the index patient’s age at diagnosis is quite
consistent with the studies reported by Peto and Mack (2000),
although the incidence does increase slightly with age. The
predicted risks to MZ twins of breast cancer cases were, however,
less than those reported by Peto and Mack (2000). Unfortunately,
the data on age-specific risks to MZ twins are limited so it is
unclear if this discrepancy is real.
The predicted incidence of contralateral breast cancer is also
markedly lower than that summarised by Peto and Mack (2000),
based on the Connecticut Tumor Registry. Our estimates are in
fact closer to those reported by Vaittinen and Hemminki (2000),
BOADICEA BRCAPRO Claus et al
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Figure 5 Predicted cancer risks for the index female of family 2 under
the following models: BOADICEA, BRCAPRO (CancerGene v3.1, http://
www3.utsouthwestern.edu/cancergene) and Claus et al (1991).
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Figure 6 Family 3 with information on age at last follow-up and age at
diagnosis. Index indicated by arrow. BC¼breast cancer.
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estimated that the contralateral breast cancer incidence is around
0.8% at age 30 years and decreases to a constant level of around
0.4% at ages 50 years and above. Contralateral breast cancers were
not a component of the original BOADICEA model but have been
incorporated into the model by assuming that, conditional on
genotype, the incidence of a breast cancer in the opposite breast is
half the overall incidence of breast cancer at the same age. The
underestimation of the contralateral risk by the BOADICEA model,
if substantiated, may indicate that additional intraindividual
factors influence risk. If so, separate parameters to allow for the
higher rate of second cancers may be required.
The current model was derived using families ascertained
through breast cancer probands, and included both mutation-
positive and mutation-negative cases (Antoniou et al, 2001, 2002).
However, the estimated incidence rates in BRCA1 and BRCA2
carriers are based on a relatively limited number of mutation-
positive families (62 in total), so these incidence rates are
somewhat imprecise. More precise penetrance estimates have been
derived in a meta-analysis of the families of BRCA1/2 carriers
identified through population-based studies of breast and ovarian
cancer (Antoniou et al, 2003). The BRCA2 penetrance function in
our model is very similar to that estimated by Antoniou et al
(2003), but the BRCA1 risks in our model are lower than the meta-
analysis estimates (35 vs 65% by age 70 years). These estimates are
not directly comparable since the BOADICEA model allows for the
polygenic component that modifies the BRCA1 and BRCA2 risks,
whereas the estimates of Antoniou et al (2003) do not allow for a
polygenic component. Moreover, those estimates were based on
the risks in relatives of breast cancer patients identified through
population-based studies, while the BOADICEA risks are the
average risks for the whole population. Nevertheless, difference in
the BRCA1 risks estimated by the BOADICEA model and the meta-
analysis of Antoniou et al (2003) suggests that the BOADICEA
model may have underestimated the BRCA1 risk. Refinement of
the BOADICEA model by refitting using additional family data is
in progress.
We have demonstrated that the predicted cancer and carrier
risks in some families differ markedly from those predicted under
other models. In our comparisons, we concentrated on the two
widely used genetic models of Claus et al (1991) and Parmigiani
et al (1998) (BRCAPRO). Other models are based on empirical
summaries of FH rather than pedigree analysis of a genetic model
(Gail et al, 1989; Shattuck-Eidens et al, 1995; Couch et al, 1997;
Apicella et al, 2003). We did not consider these models here since
they are not directly comparable; however, from our experience
these models can also give predictions that differ substantially
from BOADICEA (results not shown).
The model of Claus et al (1991) assumes a single dominant gene
with an allele frequency of 0.33%. This is clearly a considerable
oversimplification since there is no allowance for the differences in
risks between BRCA1 and BRCA2 carriers (Ford et al, 1998;
Malone et al, 2000; Antoniou et al, 2003) or for other lower risk
genes. In the examples we examined, the breast cancer risks
predicted by the Claus et al (1991) model were sometimes similar
to those predicted by BOADICEA (as in Figures 3 and 5) but
sometimes quite different (as for family 3 in Figure 6).
The BRCAPRO model is closer to BOADICEA in that BRCA1
and BRCA2 are modelled separately. The differences between
BOADICEA and BRCAPRO can be explained partly by the different
penetrance functions and allele frequencies for BRCA1 and BRCA2
assumed by the two models. Specifically, BRCAPRO assumes
BRCA1 mutations to be more prevalent than BRCA2 (Berry et al,
2002), whereas BRCA1 and BRCA2 mutations have similar
population frequencies in BOADICEA, with BRCA2 being slightly
more prevalent. We investigated the effect on predictions by
changing the allele frequencies in BRCAPRO to those assumed by
the BOADICEA model (Antoniou et al, 2002). This resulted in
somewhat higher predicted prevalence for BRCA2 mutations
among unselected breast cancer patients. BRCA2 mutations
were predicted to account for 2.4% of the patients diagnosed at
age 30 years (compared to 0.8% previously) and for 0.4%
of the patients diagnosed at age 70 years (compared to 0.1%
previously). Moreover, for ages at diagnosis of 50 years and
over BRCA2 mutations were predicted to be more prevalent
than BRCA1 mutations, a feature similar to BOADICEA. Changing
the allele frequencies in BRCAPRO did not have a marked
effect on the predicted FRRs, which were very similar
to the predictions in Table 5. Furthermore, the extent of
FH that the models consider may also be important in explaining
the differences between BOADICEA and BRCAPRO. BRCAPRO
does not consider FH information on relatives more distant
than second degree, whereas the present model can incorporate
all available relatives. In practice however, including data on
third- (or higher) degree relatives may bias the predictions
as self-reporting FH can be less reliable on these relatives
(Thompson and Schildkraut, 1991). As for the Claus et al model,
however, the most important difference is that BRCAPRO makes
no allowance for other susceptibility genes other than BRCA1 and
BRCA2.
Several improvements can be made to the present model. An
obvious deficiency (also present in other models) is that the
genotype-specific incidence rates are computed for broad age
categories (mostly 5 years). Thus, for example, the incidence rates
are assumed constant over the period 30–34, but different from
those at 29 years or age 35 years. This leads to substantial steps in
carrier probabilities and predicted risks that could be improved by
smoothing. As more data become available, we plan to refit the
model in order to obtain more accurate estimates of the BRCA1
and BRCA2 allele frequencies and penetrances and of the polygenic
component. In addition to the breast and ovarian cancer risks,
there is evidence that BRCA1 and BRCA2 mutations confer
increased risks of other cancers such as prostate cancer and
pancreatic cancer (The Breast Cancer Linkage Consortium, 1999;
Thompson and Easton, 2002). The model can be extended
straightforwardly to incorporate such information. BRCA1- and
BRCA2-associated breast cancer tumours have also been reported
to have different pathological characteristics from one another,
and also from sporadic and other familial tumours (Breast Cancer
Linkage Consortium, 1997; Lakhani et al, 1998; Lakhani et al, 2000;
Lakhani et al, 2002). Incorporating pathological information into
the model would improve the accuracy of carrier prediction. In
principle, the model can also be extended to incorporate
nongenetic risk factors, such as parity, breast feeding and age at
menopause. This, however, requires precise estimates of these
effects in BRCA1 and BRCA2 carriers.
Finally, the model can be extended to account for the effects of
other susceptibility genes. The polygenic component in BOADI-
CEA represents the combined effects of low-penetrance breast
cancer susceptibility genes. To date, only two low-penetrance
breast cancer susceptibility genes, ATM and CHEK2, have been
reliably identified (Swift et al, 1990; The CHEK2-Breast Cancer
Consortium 2002). In the case of CHEK2, the truncating variant
1100delC confers a relative risk of breast cancer approximately
two-fold; this relative risk appears to be independent of FH, and
this gene fits well as a component of a multiplicative polygenic
model. As other such genes are identified, the model can be
extended to allow explicitly for their effects.
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